Scientific article
Open access

SGLT2 inhibitors, what the emergency physician needs to know: a narrative review

Published inJournal of clinical medicine, vol. 10, no. 9, 2036
Publication date2021-05-10
First online date2021-05-10

Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin belong to a class of antidiabetic treatments referred to as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors, or SGLT2is). SGLT2is are currently indicated in North America and in Europe in type 2 diabetes mellitus, especially in patients with cardiovascular (CV) disease, high CV risk, heart failure, or renal disease. In Europe, dapagliflozin is also approved as an adjunct to insulin in patients with type 1 diabetes mellitus. New data provide evidence for benefits in heart failure with reduced ejection fraction and chronic kidney disease, including in patients without diabetes. The use of SGLT2is is expected to increase, suggesting that a growing number of patients will present to the emergency departments with these drugs. Most common adverse events are easily treatable, including mild genitourinary infections and conditions related to volume depletion. However, attention must be paid to some potentially serious adverse events, such as hypoglycemia (when combined with insulin or insulin secretagogues), lower limb ischemia, and diabetic ketoacidosis. We provide an up-to-date practical guide highlighting important elements on the adverse effects of SGLT2is and their handling in some frequently encountered clinical situations such as acute heart failure and decompensated diabetes.

  • Diabetes
  • Guidelines
  • Heart failure
  • Renal
Citation (ISO format)
LU, Henri et al. SGLT2 inhibitors, what the emergency physician needs to know: a narrative review. In: Journal of clinical medicine, 2021, vol. 10, n° 9, p. 2036. doi: 10.3390/jcm10092036
Main files (1)
Article (Published version)
ISSN of the journal2077-0383

Technical informations

Creation02/21/2022 3:37:00 PM
First validation02/21/2022 3:37:00 PM
Update time03/16/2023 6:39:36 AM
Status update03/16/2023 6:39:34 AM
Last indexation08/31/2023 8:30:41 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack